Basic information
Biomarker: DFF40
Histology type: type II EC
Cohort characteristics
Country: Poland
Region: Krakow
Study type: Representative postoperative
Followed up time :
Subgroup 1 name : Low- and moderate- grade
Subgroup 1 number: 215
Subgroup 2 name: Non-endometrioid and high-grade
Subgroup 2 number: 127
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
342 | Low- and moderate- grade endometroid endometrial cancer | 215 | Non-endometrioid and high-grade endometroid endometrial cancer | 127 |
Sample information
Conclusion: Compared with low- and moderate-grade endometrioid ECs, non-endometrioid and high-grade endometrioid ECs showed significant DFF40 and BCL2 underexpression. The absence of DFF40 and BCL2 expression negatively affects DFS and OS. Further prospective studies are warranted to assess the potential utility of DFF40 and BCL2 as targets in the diagnosis or treatment of ECs
Sample type : tissue
Sample method: immunohistochemistry
Expression pattern : under expressed(0-1 negative expression, intensity score was multiplied by the cell staining percentage score to obtain the final immunoreactivity score)
Expression elevation: The staining scores for DFF40, BCL2 and DFF45 for each slide in five high-power fields (× 40) using a 0-to-3 scale (0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining) [19, 20]. The cell staining percentage scores for DFF45 and DFF40 were determined as follows: 0 = expression in up to 10% of cells; 1+ = expression in 10–50% of cells; 2+ = expression in 51–80% of cells; and 3+ = expression in over 80% of cells. The cell staining percentage scores for BCL2 were calculated using the scale defined by Yigit et al.: 0 = expression in up to 5% of cells; 1+ = expression in 5%-25% of cells; 2+ = expression in 26%-50% of cells; and 3+ expression in over 50% of cells. The intensity score was multiplied by the cell staining percentage score to obtain the final immunoreactivity score for each protein, which ranged from 0 to 9. Final scores of 0-1 were indicative of negative protein expression, whereas scores of 2-4 were indicative of low protein expression, and scores of 6-9 were indicative of high protein expression.
Disease information
Statictics: Mean (SD)
Subgroup 1 age: 65.167 ± 6.661
Subgroup 2 age: 71.244 ± 9.599
Related information
Funtion Uniprot: Nuclease that induces DNA fragmentation and chromatin condensation during apoptosis. Degrades naked DNA and induces apoptotic morphology.
UniProt ID: O76075
UniProt Link: https://www.uniprot.org/uniprotkb/O76075/entry
Biological function from UniProt: Apoptosis
Molecular function from UniProt:
Subcellular UniProt: #Cytoplasm #Nucleus
Alternative name from UniProt:
Gene name from HGNC: DFFB (CAD, CPAN, DFF-40, DFF40)
HPA link: https://www.proteinatlas.org/ENSG00000169598-DFFB
Tissue specificity RNA from HPA: Tissue enhanced (intestine)
Cancer prognostic summary HPA Prognostic marker in urothelial cancer (favorable)
Pathology link: https://www.proteinatlas.org/ENSG00000169598-DFFB/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000169598-DFFB/pathology/endometrial+cancer
Expression figure legend: DFF40*, DFF45**, and BCL2*** expression (× 200) in different histological types of endometrial cancers.
Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899339/figure/Fig1/
Survival figure legend: Kaplan-Meier survival curves for overall and disease-free survival in DFF40*-, DFF45**-, and BCL2***-negative and positive cases in the entire study cohort and in Groups A$ and B$$,
Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899339/
OMIM: 601883
OMIM link2: https://www.omim.org/entry/601883
HGNC ID: HGNC:2773
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2773